Pfizer Expands Santaris Deal to Boost Presence in RNA-Targeted Drug Development
This article was originally published in The Pink Sheet Daily
Executive Summary
RNA-targeted medicines receive a boost from Pfizer's expansion of its strategic alliance with Danish firm Santaris